<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="30672">Ferrocene</z:chebi>-containing β-<z:chebi fb="0" ids="46640">diketones</z:chebi> and <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, [(<z:chebi fb="0" ids="16134">NH(3)</z:chebi>)(2)PtCl(2)], possess strong <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> activity </plain></SENT>
<SENT sid="1" pm="."><plain>No information is available regarding the anticancer activity of the corresponding <z:chebi fb="0" ids="30680">ruthenocene</z:chebi> complexes </plain></SENT>
<SENT sid="2" pm="."><plain>This study examined the cytotoxicity of stable <z:chebi fb="0" ids="30680">ruthenocene</z:chebi>-containing β-<z:chebi fb="0" ids="46640">diketones</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The results were related to the cytotoxicity of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and the ease of <z:chebi fb="6" ids="30682">ruthenium</z:chebi> electrochemical oxidation </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIALS AND METHODS: The <z:chebi fb="0" ids="30680">ruthenocene</z:chebi>-containing β-<z:chebi fb="0" ids="46640">diketones</z:chebi> RcCOCH(2)COR where Rc=Ru(II)(C(5)H(5))(C(5)H(4)) and R=CF(3) (1), CH(3) (2), Ph=C(6)H(5) (3) and Fc=Fe(II)(C(5)H(5))(C(5)H(4)) (4) were tested for cytotoxicity against HeLa (human cervix epithelioid) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, COR L23 (human large cell <z:mp ids='MP_0008714'>lung carcinoma</z:mp>) and the <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-resistant CoLo 320DM (human colorectal) and COR L23/CPR <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>Cell survival was measured by means of the colourimetric 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium <z:chebi fb="25" ids="15858">bromide</z:chebi> (<z:chebi fb="0" ids="53233">MTT</z:chebi>) assay </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The 50% cell growth inhibition (IC(50)) values of 1-4 towards the cells ranged between 8.2 and 84.6 μmol <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">dm</z:e>(-3), with 1 being the most cytotoxic complex </plain></SENT>
<SENT sid="7" pm="."><plain>Drug activity was directly proportional to the electron density on the <z:chebi fb="6" ids="30682">ruthenium</z:chebi> centre as well as the oxidation potential of the <z:chebi fb="6" ids="30682">ruthenium</z:chebi> core but inversely proportional to the pK(a) of the β-<z:chebi fb="0" ids="46640">diketones</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The strongest activity was observed against the COR L23 cell line, and the weakest activity against COR L23 CPR </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: A drug activity-structural relationship exists for <z:chebi fb="0" ids="30680">ruthenocene</z:chebi>-containing β-<z:chebi fb="0" ids="46640">diketones</z:chebi> in that drugs with the lowest electron density on the <z:chebi fb="6" ids="30682">ruthenium</z:chebi> centre are more cytotoxic </plain></SENT>
<SENT sid="10" pm="."><plain>Compounds with larger <z:chebi fb="6" ids="30682">ruthenium</z:chebi> oxidation potentials and stronger acid strength (i.e. smaller pK(a) values) are more cytotoxic </plain></SENT>
</text></document>